Jonathan Young is Chief Operating Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 216,286 shares of AKRO, which is worth approximately $6.63 Million. The most recent transaction as insider was on Nov 01, 2024, when has been sold 50,716 shares (Common Stock) at a price of $32.15 per share, resulting in proceeds of $1,630,519. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 216K
10.57% 3M change
41.2% 12M change
Total Value Held $6.63 Million

Jonathan Young Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 01 2024
SELL
Open market or private sale
$1,630,519 $32.15 p/Share
50,716 Reduced 18.99%
216,286 Common Stock
Nov 01 2024
BUY
Exercise of conversion of derivative security
$858,700 $21.09 p/Share
40,716 Added 13.23%
267,002 Common Stock
Oct 14 2024
SELL
Open market or private sale
$1,206,000 $30.15 p/Share
40,000 Reduced 15.02%
226,286 Common Stock
Oct 14 2024
BUY
Exercise of conversion of derivative security
$843,600 $21.09 p/Share
40,000 Added 13.06%
266,286 Common Stock
Oct 01 2024
SELL
Open market or private sale
$281,800 $28.18 p/Share
10,000 Reduced 4.23%
226,286 Common Stock
Sep 10 2024
SELL
Open market or private sale
$14,870 $26.18 p/Share
568 Reduced 0.24%
236,286 Common Stock
Sep 03 2024
SELL
Open market or private sale
$135,000 $27.0 p/Share
5,000 Reduced 2.07%
236,854 Common Stock
Aug 01 2024
SELL
Open market or private sale
$134,200 $26.84 p/Share
5,000 Reduced 2.03%
241,854 Common Stock
Jul 01 2024
SELL
Open market or private sale
$117,000 $23.4 p/Share
5,000 Reduced 1.99%
246,854 Common Stock
Jun 28 2024
BUY
Grant, award, or other acquisition
$21,216 $19.94 p/Share
1,064 Added 0.42%
251,854 Common Stock
Jun 11 2024
SELL
Open market or private sale
$56,962 $22.64 p/Share
2,516 Reduced 0.99%
250,790 Common Stock
Jun 03 2024
SELL
Open market or private sale
$96,450 $19.29 p/Share
5,000 Reduced 1.94%
253,306 Common Stock
May 01 2024
SELL
Open market or private sale
$100,750 $20.15 p/Share
5,000 Reduced 1.9%
258,306 Common Stock
Apr 01 2024
SELL
Open market or private sale
$10,008 $25.02 p/Share
400 Reduced 0.15%
263,306 Common Stoek
Apr 01 2024
SELL
Open market or private sale
$111,917 $24.33 p/Share
4,600 Reduced 1.71%
263,706 Common Stock
Mar 13 2024
SELL
Open market or private sale
$18,442 $28.33 p/Share
651 Reduced 0.24%
268,306 Common Stock
Mar 01 2024
BUY
Exercise of conversion of derivative security
$51,659 $0.62 p/Share
83,321 Added 23.65%
268,957 Common Stock
Dec 27 2023
SELL
Open market or private sale
$129,936 $24.0 p/Share
5,414 Reduced 2.84%
185,131 Common Stock
Dec 27 2023
BUY
Exercise of conversion of derivative security
$34,433 $6.36 p/Share
5,414 Added 2.76%
190,545 Common Stock
Dec 14 2023
SELL
Open market or private sale
$11,272 $20.76 p/Share
543 Reduced 0.29%
185,131 Common Stock
Dec 08 2023
BUY
Grant, award, or other acquisition
-
32,497 Added 14.9%
185,674 Common Stock
Nov 17 2023
SELL
Open market or private sale
$440,400 $14.68 p/Share
30,000 Reduced 16.38%
153,177 Common Stock
Oct 02 2023
SELL
Open market or private sale
$25,039 $51.1 p/Share
490 Reduced 0.27%
183,177 Common Stock
Oct 02 2023
BUY
Exercise of conversion of derivative security
$10,339 $21.1 p/Share
490 Added 0.27%
183,667 Common Stock
Sep 13 2023
SELL
Open market or private sale
$28,291 $50.34 p/Share
562 Reduced 0.31%
183,177 Common Stock
JY

Jonathan Young

Chief Operating Officer
South San Francisco, CA

Track Institutional and Insider Activities on AKRO

Follow Akero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO